A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL. (Q39503952)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

12 September 2017

A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL. (English)

1 reference

Europe PubMed Central

12 September 2017

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

object named as

Je-Hwan Lee

6

0 references

10

object named as

Choung-Soo Kim

1 reference

Europe PubMed Central

12 September 2017

5

object named as

In Gab Jeong

1 reference

Europe PubMed Central

12 September 2017

author name string

Jung Jin Hwang

1

1 reference

Europe PubMed Central

12 September 2017

Yong Sook Kim

2

1 reference

Europe PubMed Central

12 September 2017

Taelim Kim

3

1 reference

Europe PubMed Central

12 September 2017

Mi Joung Kim

4

1 reference

Europe PubMed Central

12 September 2017

Jene Choi

7

1 reference

Europe PubMed Central

12 September 2017

Sejin Jang

8

1 reference

Europe PubMed Central

12 September 2017

Seonggu Ro

9

1 reference

Europe PubMed Central

12 September 2017

publication date

20 July 2011

1 reference

Europe PubMed Central

12 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

12 September 2017

30

1 reference

Europe PubMed Central

12 September 2017

4

1 reference

Europe PubMed Central

12 September 2017

1434-1442

1 reference

Europe PubMed Central

12 September 2017

https://scigraph.springernature.com/pub.10.1007/s10637-011-9718-1

0 references

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Rational development of histone deacetylase inhibitors as anticancer agents: a review

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

HDAC inhibitors: clinical update and mechanism-based potential.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

The role of histone deacetylases in prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Histone deacetylase inhibitors: molecular mechanisms of action

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Histone deacetylation in epigenetics: an attractive target for anticancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Histone deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis through up-regulation of Annexin A1.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Docetaxel-based combination therapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Targeting the androgen receptor pathway in prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9718-1

21 January 2018

Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21773733

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21773733

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21773733

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA

1 reference

https://pubmed.ncbi.nlm.nih.gov/21773733

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21773733

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B

1 reference

https://pubmed.ncbi.nlm.nih.gov/21773733

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-011-9718-1

1 reference

Europe PubMed Central

12 September 2017

1 reference

Europe PubMed Central

12 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39503952&oldid=1966852379"